Suppr超能文献

针对肌萎缩侧索硬化中线粒体功能障碍的系统评价与荟萃分析。

Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis.

作者信息

Mehta Arpan R, Walters Rachel, Waldron Fergal M, Pal Suvankar, Selvaraj Bhuvaneish T, Macleod Malcolm R, Hardingham Giles E, Chandran Siddharthan, Gregory Jenna M

机构信息

UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.

出版信息

Brain Commun. 2019 Aug 6;1(1):fcz009. doi: 10.1093/braincomms/fcz009.

Abstract

Interventions targeting mitochondrial dysfunction have the potential to extend survival in preclinical models of amyotrophic lateral sclerosis. The aim of this systematic review was to assess the efficacy of targeting mitochondria as a potential therapeutic target in amyotrophic lateral sclerosis. Preclinical studies written in the English language were identified with no restrictions on publication date from PubMed, Medline and EMBASE databases. All studies adopting interventions targeting mitochondria to treat amyotrophic lateral sclerosis in genetic or drug-induced organism models were considered for inclusion. A total of 76 studies were included in the analysis. Survival data were extracted, and the meta-analysis was completed in RevMan 5 software. We show that targeting mitochondrial dysfunction in amyotrophic lateral sclerosis results in a statistically significant improvement in survival ( = 5.31; <0.00001). The timing of administration of the intervention appears to affect the improvement in survival, with the greatest benefit occurring for interventions given prior to disease onset. Interventions at other time points were not significant, although this is likely to be secondary to a lack of publications examining these timepoints. The quality score had no impact on efficacy, and publication bias revealed an overestimation of the effect size, owing to one outlier study; excluding this led to the recalculated effect size changing from 5.31 to 3.31 (<0.00001). The extant preclinical literature indicates that targeting mitochondrial dysfunction may prolong survival in amyotrophic lateral sclerosis, particularly if the intervention is administered early. A limitation of current research is a significant bias towards models based on superoxide dismutase 1, with uncertainty about generalisability to amyotrophic lateral sclerosis with an underlying TAR DNA binding protein 43 proteinopathy. However, further mechanistic research is clearly warranted in this field.

摘要

针对线粒体功能障碍的干预措施有可能延长肌萎缩侧索硬化症临床前模型的生存期。本系统评价的目的是评估将线粒体作为肌萎缩侧索硬化症潜在治疗靶点的有效性。通过PubMed、Medline和EMBASE数据库检索了不限出版日期的英文临床前研究。所有在基因或药物诱导的生物体模型中采用针对线粒体的干预措施治疗肌萎缩侧索硬化症的研究均被纳入考虑。分析共纳入76项研究。提取生存数据,并在RevMan 5软件中完成荟萃分析。我们发现,针对肌萎缩侧索硬化症中的线粒体功能障碍可使生存期在统计学上有显著改善( = 5.31;<0.00001)。干预措施的给药时机似乎会影响生存期的改善,疾病发作前给予的干预措施获益最大。其他时间点的干预措施无显著意义,不过这可能是由于缺乏研究这些时间点的出版物所致。质量评分对疗效无影响,发表偏倚显示效应量被高估,原因是有一项异常值研究;排除该研究后,重新计算的效应量从5.31变为3.31(<0.00001)。现有临床前文献表明,针对线粒体功能障碍可能会延长肌萎缩侧索硬化症的生存期,尤其是在早期给予干预措施的情况下。当前研究的一个局限性是对基于超氧化物歧化酶1的模型存在显著偏倚,对于潜在存在TAR DNA结合蛋白43蛋白病的肌萎缩侧索硬化症的可推广性存在不确定性。然而,该领域显然有必要进行进一步的机制研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f89e/7425425/b24de358db83/fcz009f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验